In the phase 1 clinical trial, MK‐5475, a selective inhaled sGC stimulator, was evaluated for safety and pharmacokinetics/pharmacodynamics in participants with PH associated with COPD (PH‐COPD). Here, SGCB is linked to chronic obstructive pulmonary disease.